Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

NCT07470840 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07470840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07470840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2027
Completion date
June 1, 2029
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic renal cell carcinoma